Contact Us
Drug Search Results
More Filters [+]

Relacorilant

Alternative Names: relacorilant, cort-125134, cort125134, cort 125134
Latest Update: 2024-12-16
Latest Update Note: News Article

Product Description

Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor that does not bind to the body's other hormone receptors.

Mechanisms of Action: GR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Corcept
Company Location: MENLO PARK CA 94025
Company CEO: Joseph K. Belanoff
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Relacorilant

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, France, Germany, Hungary, Israel, Italy, Korea, Netherlands, Poland, Romania, Spain, United Kingdom, United States

Active Clinical Trial Count: 15

Highest Development Phases

Phase 3: Adenoma|Adrenocortical Adenoma|Adrenocortical Hyperfunction|Cushing Syndrome|Fallopian Tube Cancer|Hypertension, Renal|Ovarian Cancer|Peritoneal Cancer

Phase 1: Adrenocortical Carcinoma|Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ROSELLA

P3

Active, not recruiting

Peritoneal Cancer|Ovarian Cancer|Fallopian Tube Cancer

2026-09-27

IRB18-0152

P1

Active, not recruiting

Prostate Cancer

2026-01-10

CORT125134-556

P3

Unknown Status

Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer

2025-12-31

CORT125134-452

P2

Active, not recruiting

Cushing Syndrome

2025-12-01

Recent News Events

Date

Type

Title

12/16/2024

News Article

 Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

10/30/2024

News Article

 Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update

06/24/2024

News Article

 Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific Sessions

06/03/2024

News Article

 Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing's Syndrome)

03/27/2024

PubMed

 A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.

01/01/2024

PubMed

 Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval.

08/11/2023

PubMed

 Glucocorticoid Receptor Regulates and Interacts with LEDGF/p75 to Promote Docetaxel Resistance in Prostate Cancer Cells.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions